How to Conduct China Medical Device Clinical Trials: 2026 Guide

1. Introduction: China’s Clinical Trial Landscape for Medical Devices

China has emerged as one of the world’s largest medical device markets, with a compound annual growth rate of approximately 15% over the past five years and a total market value exceeding RMB 1 trillion in 2025. For foreign medical device manufacturers seeking market access, conducting clinical trials in China is no longer optional — it is a regulatory necessity for most mid- to high-risk devices. The pathway, however, has undergone transformative changes since the implementation of NMPA Decree 15 (the Medical Device Clinical Trial Quality Management Standards), which took effect in May 2022 and aligns China’s clinical trial requirements with internationally recognized Good Clinical Practice (GCP) standards.

The National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), oversees all medical device clinical trials through its subsidiary body, the Center for Medical Device Evaluation (CMDE). Since 2022, the clinical trial notification system — a filing-based mechanism with a 60-day silent approval period — has replaced the former approval system, significantly streamlining the process for sponsors. China’s clinical trial registration platform (accessible via www.chinadrugtrials.org.cn) now serves as the central repository for all registered medical device trials, mirroring the function of ClinicalTrials.gov in the United States.

This guide provides regulatory affairs professionals with a practical, step-by-step roadmap to planning, executing, and completing medical device clinical trials in China. We cover the regulatory framework, when trials are required, the end-to-end process, timelines, costs, site selection, and critical differences from US and EU pathways.

2. When Are Clinical Trials Required?

China classifies medical devices into three categories based on risk, and the clinical trial requirement varies accordingly:

• Class I (Low Risk): No clinical trial or clinical evaluation required. The manufacturer submits a standard registration application with basic technical documentation. Examples include bandages, surgical gloves, and stethoscopes.
• Class II (Moderate Risk): Clinical evaluation is required, which may take the form of a literature-based clinical evaluation, a clinical trial, or a combination of both. In practice, approximately 30% of Class II devices qualify for exemptions under the NMPA’s Clinical Trial Exemption Catalog. The remaining 70% require at least some form of clinical data submission. Examples include electrocardiographs, infusion pumps, and ultrasound devices.
• Class III (High Risk): A full clinical trial is almost always required. Class III devices — such as coronary stents, implantable pacemakers, artificial joints, and dialysis machines — must undergo a properly designed, multi-center clinical trial conducted at no fewer than three GCP-certified hospital sites.

NMPA maintains a dynamic Clinical Trial Exemption Catalog (Miǎn Yú Lín Chuáng Shì Yàn Mù Lù) that lists specific device types exempt from clinical trial requirements. These exemptions are available only for devices whose safety and efficacy are well established through long-term clinical use and existing literature. The catalog currently covers roughly 30% of Class II devices. Devices not listed in the catalog must fulfill the standard clinical data requirements. Importantly, exemptions apply only to the clinical trial component — a clinical evaluation report supported by scientific literature and post-market surveillance data is still mandatory.

According to the NMPA 2024 Guidance for the Content of Medical Device Clinical Evaluation Reports, sponsors should submit a Clinical Evaluation Plan (CEP) early in the regulatory process to confirm whether a full clinical trial is required or whether a literature-based evaluation will suffice. Early engagement with the CMDE through the pre-submission consultation pathway is strongly recommended for Class III devices and novel Class II devices.

3. Regulatory Framework: Decree 15 and Associated Guidance

The regulatory foundation for medical device clinical trials in China rests on several key documents:

NMPA Decree 15 — Medical Device Clinical Trial Quality Management Standards (2022)

Decree 15 is China’s GCP-equivalent regulation for medical devices. It establishes standards for protocol design, ethics committee review, investigator qualifications, monitoring, data management, adverse event reporting, and record-keeping. Key provisions include:

• Mandatory ethics committee (IEC/IRB) approval before trial initiation
• Informed consent requirements aligned with the Declaration of Helsinki
• Sponsor responsibility for monitoring and auditing
• Data management standards requiring source document verification
• Requirement for the principal investigator to have at least three years of clinical trial experience
• Penalty provisions: violations can result in fines of RMB 10,000–50,000, suspension of the trial, and invalidation of all data collected (source: NMPA Decree 15, Chapter 8).

CMDE Clinical Trial Guidelines

The Center for Medical Device Evaluation publishes device-specific clinical trial guidance documents covering trial design, acceptable endpoints, sample size requirements, and statistical analysis methods. These guidelines are regularly updated and should be consulted during the protocol design phase. There are currently over 120 device-specific guidance documents available on the CMDE website.

IEC/IRB Requirements

Ethics committee approval must be obtained from each participating trial site. China requires that ethics committees be registered with the NMPA and that at least one committee member has expertise in medical ethics and law. The ethics review timeline typically ranges from 30 to 90 days, depending on the complexity of the device and the risk level of the trial.

4. The Clinical Trial Process: Step-by-Step

Conducting a medical device clinical trial in China follows a structured process. Below is the step-by-step workflow that sponsors and contract research organizations (CROs) must navigate.

1. Protocol Design and Pre-Submission Consultation. Draft the clinical trial protocol, investigator’s brochure, case report forms (CRFs), and informed consent documents. Engage with the CMDE through the pre-submission consultation process, particularly for Class III devices or novel technologies. This early engagement can save months of rework later.
2. Ethics Committee Review. Submit the protocol package to the ethics committee (IEC/IRB) at the lead trial site. Obtain formal ethics approval before proceeding. Allow 30–90 days for this step.
3. NMPA Clinical Trial Notification (Filing). Submit a trial notification through the NMPA’s online clinical trial notification system. This is a filing, not an approval — the NMPA has 60 working days to raise objections. If no objection is raised within 60 days, the trial may proceed by default (silent approval).
4. Investigator Selection and Site Qualification. Select qualified principal investigators at GCP-certified hospitals. Verify that each site has adequate facilities, patient populations, and experience with the device category. For Class III devices, a minimum of three sites is required.
5. Trial Conduct and Monitoring. Initiate patient enrollment and conduct the trial according to the approved protocol. Sponsors must appoint qualified monitors who perform regular site visits (typically every 4–8 weeks) to verify data accuracy and protocol compliance. All adverse events must be reported within 24 hours for serious events and within 7 days for non-serious events.
6. Data Collection and Statistical Analysis. Collect data using validated electronic data capture (EDC) systems. Perform statistical analysis according to the pre-defined Statistical Analysis Plan (SAP). The analysis must be conducted by a qualified biostatistician, and the results must be presented in a comprehensive Clinical Study Report (CSR).
7. Final Report Submission. Compile the final clinical trial report and submit it as part of the medical device registration application (NMPA Form 10). The CMDE reviews the clinical data within the standard 90–120 working day review timeline for Class III devices.

5. Timelines and Costs

The duration and cost of a medical device clinical trial in China vary significantly based on device class, trial complexity, patient enrollment rates, and the number of trial sites. The table below provides current estimates based on 2025–2026 industry data.

The wide cost ranges reflect differences in device complexity, disease prevalence (which affects enrollment speed), the number of trial sites, and whether the device requires extended follow-up — such as 12-month or 24-month safety data for implantable devices. According to a 2025 survey by the China Regulatory Science Forum, the average cost of a Class III cardiovascular device trial in China is approximately RMB 12 million, compared to roughly RMB 8 million for an orthopedic device trial.

6. Multi-Center Trials and Site Selection

China mandates multi-center clinical trials for Class III medical devices, requiring participation from a minimum of three GCP-certified clinical trial sites. The rationale is to ensure that safety and efficacy data are representative of China’s diverse patient population spread across different geographic regions, ethnic backgrounds, and healthcare settings.

Selecting the right trial sites is one of the most consequential decisions a sponsor can make. Below are the top clinical trial institutions by reputation, patient volume, and regulatory compliance record:

• Peking Union Medical College Hospital (Beijing) — Widely regarded as China’s premier clinical research institution, with over 200 active medical device trials and the fastest ethics review turnaround among Class A tertiary hospitals.
• Fudan University Zhongshan Hospital (Shanghai) — A leading site for cardiovascular and implantable device trials, with an experienced GCP unit and a dedicated medical device clinical trial center.
• Chinese PLA General Hospital (Beijing) — One of the largest trial sites by patient enrollment volume, particularly strong in surgical and orthopedic device studies.
• West China Hospital, Sichuan University (Chengdu) — A top choice for trials requiring access to western China’s patient population, with strong capabilities in gastroenterology and neurology device studies.
• Guangdong Provincial People’s Hospital (Guangzhou) — Leading center in southern China for cardiovascular and respiratory device trials.
• Shanghai Jiao Tong University Ruijin Hospital (Shanghai) — Excellent for endocrine and metabolic device studies, with a well-established clinical research infrastructure.

For multi-center trials, sponsors must designate a lead principal investigator (PI) who takes overall responsibility for the trial conduct. The lead PI typically chairs the trial steering committee and coordinates data collection standards across sites. Data from all sites is pooled for the final analysis, and the clinical study report must include a site-by-site breakdown of patient demographics, enrollment numbers, and adverse event rates.

7. Key Differences from US/EU Clinical Trials

Foreign sponsors familiar with US FDA or EU MDR clinical trial requirements will encounter several important differences when conducting trials in China:

Sample Size Requirements

China’s CMDE often demands larger sample sizes than FDA or EU notified bodies for equivalent device categories. For example, a coronary stent trial that might require 300 patients in the United States could require 500–600 patients in China. The CMDE’s statistical guidance emphasizes greater statistical power to account for population heterogeneity across China’s provinces.

China-Specific Endpoints

While China increasingly aligns with international endpoint standards, the CMDE may require additional China-specific endpoints, particularly for:

• Endpoints that reflect Chinese clinical practice patterns (e.g., preference for drug-eluting stents over bare-metal stents, which differs from Western practice)
• Subgroup analyses by ethnic group (Han Chinese vs. minority populations)
• Quality-of-life measures validated for Chinese populations

Ethnic Sensitivity Analysis

When submitting foreign clinical data as part of a China marketing authorization application, sponsors must perform an ethnic sensitivity analysis. Adapted from ICH E5 principles (originally developed for pharmaceuticals), this analysis examines whether differences in genetics, diet, environment, and medical practice between the foreign population and the Chinese population could affect the device’s safety or efficacy profile. If the analysis reveals significant concerns, the CMDE may require a full or partial China-specific clinical trial even if a device is already approved in the US, EU, or Japan.

Requirement for China-Specific Clinical Data

Unlike the European Union, which accepts clinical data from any recognized jurisdiction under MDR (subject to equivalence), China generally requires that at least some clinical data be generated from the Chinese population. For most Class III devices and novel Class II devices, this means a formal clinical trial conducted at Chinese sites. The exception is for devices with well-established safety profiles and strong international clinical data, where the CMDE may accept a bridging study — a smaller, focused trial designed to demonstrate that foreign clinical data are applicable to the Chinese population.

GCP Inspection and Enforcement

China has significantly increased its GCP inspection capacity. The NMPA’s Center for Food and Drug Inspection (CFDI) conducts both routine and for-cause inspections of clinical trial sites. Penalties for GCP violations include fines of RMB 10,000–50,000, suspension of the trial, and potential invalidation of all clinical data — which can set a registration timeline back by 12–24 months. According to the NMPA 2024 enforcement report, 22 clinical trial sites received warnings or penalties, and 3 trials were suspended for data integrity violations.

8. Clinical Trial Exemptions

The NMPA’s Clinical Trial Exemption Catalog (last updated in 2024) provides a practical pathway for certain device types to avoid the expense and delay of a full clinical trial. The catalog currently includes approximately 1,000 device types, concentrated in the following categories:

• Basic surgical instruments (forceps, scissors, retractors)
• Diagnostic imaging accessories (X-ray cassettes, ultrasound gel, MRI coils)
• Common dental materials (impression materials, cements, orthodontic brackets)
• General hospital consumables (syringes without medication, infusion sets, catheters)
• Certain in vitro diagnostic (IVD) reagents classified as Class II devices

To qualify for an exemption, a device must meet the following criteria:

1. The device has a well-established safety and efficacy profile with at least five years of documented clinical use worldwide.
2. The device is listed in the current edition of the Clinical Trial Exemption Catalog.
3. The manufacturer submits a comprehensive Clinical Evaluation Report (CER) based on literature review, post-market surveillance data, and — where applicable — clinical data from other jurisdictions.
4. The device’s working principle, materials, and intended use are not novel compared to existing exempted devices.

Even when a clinical trial is not required, the CER must be rigorous. The CMDE has rejected CERs that rely too heavily on manufacturer internal data without adequate independent literature support. A robust CER typically cites 30–50 peer-reviewed publications, includes a systematic literature search strategy, and presents a detailed risk-benefit analysis.

For sponsors unsure whether their device qualifies for an exemption, the pre-submission consultation pathway with the CMDE is the most reliable way to obtain a definitive answer. The consultation process takes approximately 30–60 working days and provides a written response that can be referenced in the subsequent registration submission.

9. Where to Go From Here

Navigating China’s medical device clinical trial requirements demands careful planning, local expertise, and up-to-date regulatory knowledge. Whether you are preparing a Class III clinical trial or exploring exemption pathways for a Class II device, the following resources from China Gateway 360 can help you build your registration strategy:

• Complete Guide to NMPA Medical Device Registration (2026) — A step-by-step walkthrough of the full registration process, including clinical data requirements, dossier preparation, and review timelines.
• Selecting a China CRO for Medical Device Trials — Practical criteria for evaluating and contracting with China-based contract research organizations, including qualification checks, pricing benchmarks, and audit readiness.
• Navigating NMPA GCP Inspections: A Pre-Audit Checklist — A compliance-focused resource covering inspection readiness, common findings, and remediation strategies for trial sites and sponsors.

Medical device clinical trials in China have become more transparent, predictable, and aligned with international standards since the implementation of Decree 15. The 60-day notification system, expanded exemption catalog, and maturing GCP inspection framework all contribute to an increasingly business-friendly environment. However, success still hinges on meticulous planning, early engagement with regulators, and careful selection of trial sites and partners. By following the framework outlined in this guide, regulatory affairs professionals can reduce uncertainty, control costs, and accelerate their path to China market access.

How to Conduct China Medical Device Clinical Trials: 2026 Guide — first published on China Gateway 360. Last updated: July 2026.